Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROBUPHINE vs BRIXADI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.
Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.
Treatment of opioid dependence,Off-label: management of chronic pain,Off-label: treatment of opioid-induced constipation
FDA-approved for the treatment of opioid use disorder (opioid dependence) as part of a comprehensive treatment plan
Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.
Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.
Terminal elimination half-life: 37 hours (range 24-48 h) due to slow release from tissue binding and enterohepatic recirculation; contributes to prolonged dosing interval (every 4 weeks) and delayed withdrawal onset.
Terminal half-life approximately 470–500 hours (~20 days) following intramuscular injection, allowing weekly or monthly dosing.
Primarily metabolized by CYP3A4 and CYP2B6 to norbuprenorphine (active). Glucuronidation via UGT1A1 and UGT2B7.
Primarily metabolized by CYP3A4 to norbuprenorphine (active metabolite) via N-dealkylation; also undergoes glucuronidation.
Primarily renal (70-80% as unchanged drug and active metabolite norbuprenorphine), biliary/fecal (20-30%)
Primarily fecal (80–90%) as unchanged drug; renal elimination accounts for <5% of the dose.
96% bound to plasma proteins (primarily alpha- and beta-globulins, minor albumin binding)
Approximately 99% bound to plasma proteins, primarily albumin and alpha1-acid glycoprotein.
Vd: 2.5-3.0 L/kg; large distribution due to high lipophilicity and extensive tissue binding, indicating slow redistribution.
Volume of distribution is very large, approximately 500–1000 L (about 5–10 L/kg in a 70 kg individual), indicating extensive tissue binding and sequestration.
Sublingual: 30-50% (due to first-pass metabolism). Transdermal: 15-20% (rate-controlled delivery). Oral: <10% (extensive first-pass) and not clinically used.
Intramuscular injection: bioavailability is nearly 100% due to limited first-pass metabolism; oral bioavailability is <5% due to extensive first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. For severe (Cr Cl <30 m L/min): not recommended.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m2) or end-stage renal disease, use with caution and consider dose reduction due to potential accumulation; specific dosing guidelines not established.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh Class A (mild): No adjustment. Child-Pugh Class B (moderate): Start at lower dose and titrate cautiously; maximum recommended weekly dose 16 mg, monthly dose 96 mg. Child-Pugh Class C (severe): Not recommended due to lack of data.
Weight-based: 0.1-0.2 mg/kg sublingually once daily, titrate up to maximum 0.4 mg/kg/day; maximum 24 mg/day.
Not approved for use in pediatric patients; safety and efficacy not established.
Start at lower end of dosing range (e.g., 4-8 mg sublingually once daily) with cautious titration due to increased sensitivity and risk of CNS depression.
No specific dose adjustments recommended; geriatric patients may have increased sensitivity and should be monitored closely for sedation, respiratory depression, and QTc prolongation. Initiate at lower end of dosing range if severe renal or hepatic impairment present.
Risk of respiratory depression, especially with concurrent use of CNS depressants or in patients with compromised respiratory function. Risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Potential for life-threatening QT prolongation at high doses.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of harm or death from accidental ingestion; concomitant use of benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Severe respiratory depression; misuse and abuse potential; neonatal opioid withdrawal syndrome; adrenal insufficiency; hepatotoxicity; QT prolongation; dental decay with sublingual use; opioid withdrawal syndrome with naloxone coadministration.
May cause respiratory depression; risk of abuse potential; need to monitor for hepatic dysfunction; adrenal insufficiency; QT prolongation; precipitation of withdrawal if initiated too soon after full agonist opioids; impairment of mental/physical abilities.
Hypersensitivity to buprenorphine; severe respiratory depression; acute or severe bronchial asthma; paralytic ileus; use of monoamine oxidase inhibitors within 14 days.
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days.
No specific food interactions are reported for buprenorphine. However, grapefruit and grapefruit juice may theoretically affect metabolism via CYP3A4 inhibition, altering drug levels. Avoid excessive intake.
No specific food interactions are reported for BRIXADI. However, patients should avoid alcohol and grapefruit juice as they may potentiate CNS depression or alter metabolism (grapefruit inhibits CYP3A4, which metabolizes buprenorphine, potentially increasing levels). Advise a balanced diet without restrictions beyond general health recommendations.
Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are no adequate human studies. First trimester exposure may be associated with neural tube defects; second and third trimester exposure may cause fetal hydantoin syndrome (craniofacial anomalies, growth retardation, neurodevelopmental delay) and increased risk of hemorrhage due to vitamin K depletion.
Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.
Probupine is excreted into breast milk. M/P ratio is approximately 0.45. Infant daily dose is estimated at 1-5% of maternal weight-adjusted dose. Reports of sedation and poor suckling in breastfed infants; cautious use recommended, especially in neonates with UDP-glucuronosyltransferase deficiency.
Unknown if excreted in human milk; no M/P ratio available. Consider risks and benefits; avoid breastfeeding if possible.
Increased hepatic clearance during pregnancy, especially third trimester, necessitating dose increases up to 30-50% to maintain therapeutic levels. Postpartum dose should be reduced to prepregnancy levels within 2 weeks. Monitor trough levels every 2 weeks during pregnancy and adjust accordingly.
No standard dose adjustment; increased clearance in pregnancy may require dose titration to effect. Monitor for withdrawal or inadequate response.
Probupine is not a recognized drug; verify spelling. If referring to buprenorphine, note that it is a partial mu-opioid agonist used for opioid use disorder and pain. Monitor for respiratory depression, especially when combined with CNS depressants. Due to its partial agonist activity, it has a ceiling effect for respiratory depression. High doses may precipitate withdrawal in opioid-dependent patients. Naloxone may not fully reverse buprenorphine effects; consider higher doses or respiratory support.
BRIXADI (buprenorphine extended-release) is a monthly subcutaneous depot formulation for opioid use disorder (OUD). Initiate only after patient is stabilized on transmucosal buprenorphine (e.g., 8–24 mg/day for at least 7 days). Do not use in opioid-naive patients due to risk of precipitated withdrawal. Administer subcutaneously in the abdomen; avoid intramuscular or intravenous injection. Monitor injection site for nodules, granulomas, or infection. Concomitant use with benzodiazepines or CNS depressants requires careful monitoring due to additive respiratory depression. Liver function tests should be monitored periodically due to risk of hepatic injury. BRIXADI contains buprenorphine as the free base, not salt; dose strengths (64 mg, 96 mg, 128 mg) are not equivalent to other buprenorphine formulations. Upon discontinuation, patients may experience prolonged withdrawal due to slow release over weeks.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol, benzodiazepines, and other sedatives unless directed by your physician, as they increase risk of serious side effects.,Do not stop suddenly; withdrawal may occur. Follow a tapering schedule if discontinuing.,Keep out of reach of children and others; misuse can cause addiction, overdose, or death.,Store safely at room temperature, away from moisture and heat.
BRIXADI is a once-monthly injection to treat opioid dependence and must be given by a healthcare provider only.,Do not attempt to self-administer or remove the injection. The medicine is released slowly over one month.,Notify your doctor immediately if you have trouble breathing, excessive drowsiness, or severe dizziness, especially when combined with alcohol or sedatives.,Avoid use of other opioids (prescription or illicit), as serious side effects including coma or death may occur.,Report any signs of liver problems: dark urine, yellowing skin/eyes, persistent nausea, or abdominal pain.,The injection site may become red, swollen, or painful; contact your doctor if these persist or worsen.,Do not stop BRIXADI suddenly; withdrawal symptoms may occur and can be prolonged.,Keep out of reach of children and pets; accidental exposure can be fatal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROBUPHINE vs BRIXADI, answered by our medical review team.
PROBUPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist. Also inhibits norepinephrine and dopamine reuptake.. BRIXADI is a Opioid Partial Agonist that works by Buprenorphine is a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors, reducing opioid withdrawal symptoms and cravings.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROBUPHINE and BRIXADI depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROBUPHINE is: Sublingual: 8 mg to 24 mg once daily initially, then 12-16 mg once daily; maximum 24 mg/day.. The standard adult dose of BRIXADI is: Brixadi (buprenorphine) extended-release injection for subcutaneous use: Patients on transmucosal buprenorphine products, after a single dose of 8-24 mg transmucosal buprenorphine, administer Brixadi as a subcutaneous injection once weekly: 8 mg/week for patients on 8-16 mg/day transmucosal buprenorphine, 16 mg/week for patients on 12-24 mg/day, 24 mg/week for patients on 16-24 mg/day. Alternatively, monthly injection: 64 mg/month for patients on 8-16 mg/day, 96 mg/month for patients on 12-24 mg/day, 128 mg/month for patients on 16-24 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROBUPHINE and BRIXADI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROBUPHINE is classified as Category C. Probupine is classified as FDA Pregnancy Category C. In animal studies, it caused fetal harm (increased resorption, skeletal anomalies) at doses 0.5 times the human dose. There are. BRIXADI is classified as Category C. Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Risk cannot be excluded; use only if benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.